SELLAS Life Sciences Group Inc sell nvestor
Start price
02.04.22
/
50%
€3.71
Target price
02.04.23
€1.00
Performance (%)
-16.30%
End price
16.04.22
€3.11
Summary
This prediction ended on 16.04.22 with a price of €3.11. The prediction for SELLAS Life Sciences Group Inc closed with a convincing performance of -16.30%. nvestor has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
SELLAS Life Sciences Group Inc | -4.960% | -4.960% | -14.162% |
iShares Core DAX® | 1.056% | 1.056% | 18.108% |
iShares Nasdaq 100 | -1.886% | -0.160% | 26.970% |
iShares Nikkei 225® | 2.553% | 4.359% | 17.676% |
iShares S&P 500 | -0.434% | 0.224% | 24.986% |
Comments by nvestor for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Sell mit Kursziel 1,0
In the thread Trading SELLAS Life Sciences Group Inc
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.